About Us
Attivare Therapeutics was established by a team from the Wyss Institute at Harvard to address the challenge of treating tumors with low immunogenicity. We are developing an off-the-shelf solution that generates a personalized immune response targeting the patient’s own tumor antigens. We are doing this by advancing the development of the AttImmune platform based on our biomaterial scaffold that can recruit, reprogram, and release target immune cells. The AttImmune platform provides 3D spatiotemporal control of bioactive components, which substantially increases both the magnitude and durability of patient immune responses. In addition, our platform synergizes with standard of care and has applications beyond oncology including the treatment of infectious diseases.
Technology
The ATTimmune technology utilizes a biomaterial to create new physical microenvironment within the body in which immune cells can be concentrated, while simultaneously delivering immunomodulatory agents to these resident cells to effectively reprogram the immune response and break tolerance to cancer antigens.
Our Team
Joaquim Trias
Chairman of the Board
Robert Pierce, MD
CSO
Ed Doherty
CTO/Co-Founder
Jess McDonough
COO/ Co-Founder
Fernanda Langellotto
Associate Director,
Co-founder
Ben Seiler
Scientist, Co-Founder
Dave Mooney
Co-Founder Professor, Harvard University School of Engineering and Applied Sciences
Lindsay Donald
Toxicology
Valentia Lee- Brotherton
Regulatory